On August 21st, the "China Pharmaceutical Science and Technology Innovation and Development Summit Forum" was held in Beijing. Hosted by the Chinese Pharmaceutical Association and several of its specialized committees, the event brought together leading experts to discuss ways to enhance China's medical science and technology innovation and drive the sustainable growth of the pharmaceutical industry. The participants emphasized that technological innovation is essential for upgrading China’s pharmaceutical sector. While the country has made progress in scientific capabilities, there are still significant challenges to overcome.
The central government has consistently supported technological advancement, aiming to transform China into an innovative nation. Policies such as institutional reforms, increased investment in research, and talent development have been implemented to foster innovation. Academician Sang Guowei, vice chairman of the National People's Congress Standing Committee and chairman of the China Pharmaceutical Association, highlighted the State Council's release of "Several Policies to Promote the Accelerated Development of the Biotechnology Industry," which aims to establish biotechnology as a key pillar of China’s economy.
Additionally, the "Eleventh Five-Year" Science and Technology Major Project "Major New Drug Creation," with a budget of 6.6 billion yuan, was launched this year. These initiatives are expected to significantly boost the pharmaceutical industry's innovation capacity. It is projected that the total output value of the pharmaceutical industry will reach 100 billion yuan by 2009, reflecting a 20% increase.
During the forum, Sang Guowei shared updates on the progress of the "Major New Drug Creation" project. Over 98% of the research tasks under the Eleventh Five-Year Plan had been initiated by April of this year, with funding allocated for 121 projects and 874 more under review. Several new drugs, including a Helicobacter pylori vaccine with a 72.1% protection rate—among the highest globally—have already received new drug approvals. Other developments include completed research on anti-drug-resistant L-ortrazole and ongoing phase III clinical trials for 43 new drugs, including Hembofen, an anti-tumor medication.
Moreover, Shanghai Institute of Traditional Chinese Medicine developed Cetoxine Hydrochloride, a new class of antibiotic, after 16 years of research. In 2007, Tsinghua University's recombinant human endostatin was approved in the U.S. Nearly two-thirds of these new drugs represent entirely new chemical structures and therapeutic targets in China.
Wang Dongjin, president of the China Medical Insurance Research Association, emphasized that medical technology innovation is at a pivotal moment. The national reform document underscores the need to build a sustainable mechanism for medical innovation and talent development. Increased investment, system reforms, and collaboration between institutions are critical for advancing medical research and improving public health.
He also called for better policy environments to support innovation, including financial incentives, tax policies, and patent protections for new drugs. Such measures would help reduce R&D risks and encourage more enterprises to invest in innovation.
Professor Zhao Zhigang from Capital Medical University highlighted the differences between China and the U.S. in their new drug innovation systems. The U.S. government focuses on creating a legal framework, fostering university-industry partnerships, and protecting intellectual property. Since the 1980s, over 20 regulations have been enacted to support innovation, providing continuous momentum for drug development.
Zhao stressed that innovative drugs are vital for economic growth and reflect a nation’s innovation capability. Their development requires strong policy and financial backing, which is especially crucial in China today.
Window Shutter,Aluminum External Louvers,Window Louvers,Air Conditioning Shutters
Xuzhou Guifeng Metal Technology Co., Ltd , https://www.guifengmetal.com